R. Tidwell

发表

Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update

Diane D. Liu, J. Lee, Ying Yuan, 2019, Clinical trials.

Potential Influence on Clinical Trials of Long-Term Survivors of Stage IV Non-small cell Lung Cancer

J. Lee, E. Szabo, Anish Thomas, 2019, JNCI cancer spectrum.

Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities

J. Wargo, P. Sharma, Jianjun Gao, 2019, Proceedings of the National Academy of Sciences.

Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2020, Leukemia & lymphoma.

Predictive capacity of a miRNA panel in identifying teratoma in post‐chemotherapy consolidation surgeries

G. Calin, C. Wood, S. Anfossi, 2022, BJUI compass.

Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).

M. Konopleva, Z. Estrov, M. Andreeff, 2020 .

Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment

P. Sharma, J. Allison, C. Logothetis, 2021, Journal for ImmunoTherapy of Cancer.

A heavy metal baseline score predicts outcome in acute myeloid leukemia

F. Albarède, J. Cortes, A. Plesa, 2020, American journal of hematology.

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

P. Sharma, C. Dinney, Jianjun Gao, 2020, Nature Medicine.

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, The Lancet. Haematology.

Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer

P. Thall, P. Sharma, P. Troncoso, 2020, Science Translational Medicine.

Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma

K. Ahrar, E. Jonasch, C. Wood, 2021, Nature Communications.

Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components

Wei Lu, J. P. Long, I. Wistuba, 2022, Cancers.

Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer

T. Ho, P. Tamboli, E. Jonasch, 2020, Clinical Cancer Research.

A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN), metastasectomy (MS) or post-treatment biopsy (Bx).

K. Ahrar, E. Jonasch, C. Wood, 2018 .

MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers

J. Roth, I. Wistuba, T. Ho, 2022, Nature Communications.

Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma

Jeffrey E. Lee, R. Wolff, M. Overman, 2021, Annals of surgery.

Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma.

E. Jonasch, N. Tannir, R. Tidwell, 2019, Clinical genitourinary cancer.

Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer.

Joe Y. Chang, R. Mohan, J. Ajani, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

M. Konopleva, Z. Estrov, M. Andreeff, 2020 .

Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases

Young Uk Kim, I. Wistuba, J. Vauthey, 2021, Clinical Cancer Research.

A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC).

P. Sharma, C. Dinney, Jianjun Gao, 2019, Journal of Clinical Oncology.

Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC).

P. Thall, C. Taniguchi, J. Holmlund, 2020, International journal of radiation oncology, biology, physics.

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.

P. Vyas, M. Konopleva, H. Kantarjian, 2021, Blood cancer discovery.

Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma

J. Shen, M. Overman, K. Fournier, 2023, JAMA network open.

Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)

C. Drake, P. Sharma, P. Troncoso, 2023, Journal for ImmunoTherapy of Cancer.

Results of a Phase II Randomized Trial of Proton Beam Therapy vs Intensity Modulated Radiation Therapy in Esophageal Cancer

P. Thall, R. Mohan, J. Ajani, 2019, International Journal of Radiation Oncology*Biology*Physics.

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.

P. Vyas, M. Konopleva, H. Kantarjian, 2023, Blood cancer discovery.

Increasing referral of at‐risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center

B. Arun, Sukh Makhnoon, S. Peterson, 2021, Cancer.

Phase II study of cladribine, idarubicin, and ara‐C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia

M. Konopleva, G. Garcia-Manero, E. Shpall, 2023, American journal of hematology.